Impact of Radiotherapy on Survival in Breast Cancer Patients

June 3, 2026 updated by: Fereshteh Abbasvandi, Motamed Cancer Institute

Impact of Radiotherapy on Disease-Free and Overall Survival in Breast Cancer Patients: A Retrospective Cohort Study

In this study, using a large retrospective cohort, the investigators evaluate the impact of RT on disease-free survival and overall survival of patients with BC. The aim is to determine the true role of radiotherapy in improving patient outcomes and to provide a basis for designing more precise treatment strategies in the future.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

BC patients diagnosed between January 1998 and February 2008 were identified from prospectively maintained breast cancer registries in the Motamed Breast Cancer Research in Tehran, Iran.

Description

Inclusion Criteria:

-BC patients diagnosed between January 1998 and February 2008 in the Motamed Breast Cancer Research in Tehran, Iran.

Exclusion Criteria:

  • Male patients.
  • Patients with missing LPFS and OS information (zero encounter/follow-up).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Breast Cancer Patients who underwent RT
Radiation: radiotherapy
Radiotherapy after BCS surgery in accordance to standard breast cancer guidelines
Breast Cancer Patients who did not underwent RT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Survival
Time Frame: 25 years
25 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Motamed Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 1998

Primary Completion (Actual)

February 1, 2008

Study Completion (Actual)

January 1, 2025

Study Registration Dates

First Submitted

May 28, 2026

First Submitted That Met QC Criteria

June 3, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 3, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IR.SUMS.REC.1405.141

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on radiotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe